Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EBS
HoldUnloved QualityFLAGEmergent BioSolutions Inc. · Healthcare · United States · $303M · Avg Vol: $8M/d
Emergent BioSolutions has value V73 with a buyback on file, but momentum at M43 is below the calibrated floor, and insiders sold 0.13%, which is separately adverse.
COMPANY DESCRIPTION
Emergent BioSolutions Inc. is a biopharmaceutical company focused on providing specialized products that address public health threats, including medical countermeasures and vaccines. The company develops, manufactures, and commercializes products for anthrax, smallpox, and opioid overdose, serving government agencies and commercial markets. Its unique focus on biodefense and public health readiness establishes a niche market leadership with long-term government contracts.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1B | 1.0B | 1.0B | 705.2M | -13.1% | 770.2M | 623.7M | 667.6M | -2.7% |
| EPS | -4.47 | -14.85 | -3.60 | 0.98 | — | -3.41 | 0.61 | — | -37.9% |
| Shares | 50.1M | 52.2M | 54.3M | 52.1M | +4.0% | 51.3M | — | — | — |
| Debt | 1.4B | 860.2M | 663.7M | 572.1M | -25.9% | 588.2M | — | — | — |
| Equity | 1.4B | 649.3M | 482.8M | 522.6M | -27.8% | — | — | — | — |
| Op CF | -34.1M | -206.3M | 58.7M | 170.6M | 190.6% | 97.7M | — | — | — |
| Inv CF | -381.3M | 212.3M | 125.2M | 69.4M | — | — | — | — | — |
| Fin CF | 481.2M | -535.7M | -190.0M | -136.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EBS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EBS | Emergent BioSolutions Inc.(you) | $303M | 64 | Hold |
| ANIK | Anika Therapeutics, Inc. | $282M | 64 | Hold |
| CL.CN | Cresco Labs Inc. | $291M | 43 | Hold |
| EOLS | Evolus, Inc. | $587M | 55 | Hold |
| TKNO | Alpha Teknova, Inc. | $382M | 44 | Hold |
| COLL | Collegium Pharmaceutical, Inc. | $786M | 72 | Buy |
| XERS | Xeris Biopharma Holdings, Inc. | $1.5B | 60 | Hold |
| GRIN.CN | Grown Rogue International Inc. | $111M | 46 | Hold |
| SIGA | SIGA Technologies, Inc. | $220M | 30 | Sell |
| JUSH.CN | Jushi Holdings Inc. | $110M | 43 | Hold |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%